Russia's Generium to establish MabThera analogue production

Generium Group of Companies, one of Russia’s largest producers of innovative drugs, has commissioned a new plant for the production of pharmacological substances and drugs in the Petushinsky area of the Vladimir region.

Establishment of the plant is part of the Russian government’s plans for the substitution of some high priced imported drugs by the domestic production. It is planned that the new plant will specialize on the production of drugs for the treatment rare diseases and cancer, as well as hemophilia, and acute circulatory disorders, such as heart attacks and strokes.

It is planned that among the priorities of the new facility will be the design and production of an analogue (or biosimilar) of cancer drug MabThera (rituximab, from Swiss drug major Roche [ROG: SIX]), as well as other analogues of some well-known Western drugs.